{"@id":"https://bioecon.ru/technology/radioligand-therapy/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://bioecon.ru/technology/radioligand-therapy/","json":"https://bioecon.ru/api/v1/technology/radioligand-therapy/index.json"},"id":"radioligand-therapy","industries":["pharma","biomanufacturing"],"lang":"ru","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/johnson-johnson/","https://bioecon.ru/companies/astrazeneca/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/cryoport-systems/","https://bioecon.ru/companies/zero-cow-factory/","https://bioecon.ru/companies/21st-bio/","https://bioecon.ru/companies/pbs-biotech/","https://bioecon.ru/companies/minicircle/","https://bioecon.ru/companies/anft-association-of-nature-forest-therapy/"]},"maturity":7,"name":"Таргетная радионуклидная терапия (РЛТ)","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"Синтез бифункциональных хелаторов"},{"n":2,"title":"Радиохимическое мечение"},{"n":3,"title":"Микродозиметрия и цитотоксичность"},{"n":4,"title":"Клиническая валидация"}],"summary":"Прецизионные радиофармпрепараты, связывающие таргетные лиганды с альфа- (свинец-212, актиний-225) или бета-излучателями (тербий-161, лютеций-177) для адресного разрушения опухолевой ДНК.","url":"/technology/radioligand-therapy/","verified":"2026-11-22"}